Medindia

X

Helicobacter pylori Antibiotic Treatment of Peptic Ulcer May not Prevent Gastric lymphomas

by Medindia Content Team on  August 28, 2005 at 3:06 PM General Health News   - G J E 4
Helicobacter pylori Antibiotic Treatment of Peptic Ulcer May not Prevent Gastric lymphomas
Stanford, CA -- Successful eradication of Helicobacter may not prevent future aggressive gastric lymphoma since resting B cells are left behind. This was reported by Research led by Dr. Anne Mueller at Stanford University School of Medicine.
Advertisement

The paper by Mueller et al., "The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced MALT lymphoma," appears in the September issue of The American Journal of Pathology.

Advertisement
Helicobacter pylori, a spiral bacterium of the stomach, infects more than half of the world's population. It is now widely accepted that, aside from gastritis and ulcers, H. pylori is also a causative agent of gastric lymphoma, specifically gastric B cell lymphoma of mucosa-associated lymphoid tissue (MALT). While antibiotic treatment eradicates the bacteria and promotes tumor regression, the effects of re-infection on disease are more severe.

Dr. Mueller's group used a mouse model of Helicobacter-induced MALT lymphoma that employs H. felis to mimic human disease in the mouse. Mice were infected with H. felis and maintained for 18 months before being assigned to one of three treatment groups: 1) no treatment (primarily infected), 2) antibiotic therapy to eradicate bacteria, or 3) antibiotic therapy followed by re-infection.

As expected, low-grade MALT lymphoma occurred in 35% of all infected animals. However, frank MALT lymphoma was more prevalent in re-infected animals (44%) than in primarily infected animals (25%). The significance of the described work is that gastric lymphoma progresses more rapidly upon secondary infection. Because resting B cells are left behind following antibiotic treatment, re-infection by H. pylori promotes the existing B cells to progress quickly into tumors. Therefore, it is important that treated patients be carefully monitored for H. pylori re-infection.

Ref: Mueller O 'Rourke J, Chu P, Chu A, Dixon MF, Bouley DM, Lee A, Falkow S: The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced MALT lymphoma. Am J Pathol 2005, 167:797-812

Research was supported by the National Institutes of Health (US), the Emmy-Noether-Program of the Deutsche Forschungsgemeinschaft (Germany), and J National Health and Medical Research Council (Australia).

Contact: Audra Cox acox@asip.org 301-634-7409 American Journal of Pathology

(Sourece: www.eurekalert.org)

Further Information on Medindia on H.Pylori:

H.Pylori testing recommended in patients with peptic ulcer: Researchers in the United States have found that the practice of testing and treating H.Pylori has steadily increased over the past 14 years. However, they suggested that patients with confirmed peptic ulcer disease should be tested for Helicobacter Pylori(H.Pylori) infection rather than receiving treatment for the infection as a matter of course. Testing was a more appropriate option than empiric treatment in patients with peptic ulcer disease, as the prevalence of H.Pylori was found to be only 36 percent.

Click here to read more:

http://www.medindia.net/news/view_news_main.asp?t=gn&x=1834
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All